Phase I clinical trials of MRX-115: A new ultrasound contrast agent

Thomas A. Fritz, Evan C Unger, George Sutherland, David Sahn

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

RATIONALE AND OBJECTIVES. Stabilized microbubbles are under development as contrast agents for medical ultrasound. The authors report the results of Phase I clinical trials of a new ultrasound contrast agent based on lipid- encapsulated perfluorocarbon gas microbubbles. METHODS. Lipids encapsulating perfluoropropane gas (Aerosomes® MRX-115, ImaRx Pharmaceutical Corp., Tucson, AZ) were evaluated in Phase I clinical trials. Two separate studies were performed. The first was a single escalating-dose study (n = 30 subjects), and the second was a multiple-dose study (n = 18 subjects) with rechallenge in several subjects (n = 4) after 21 days. Echocardiographic examinations were performed before and after contrast agent for each test drug administration for both studies, with the exception of the rechallenge group. Doses tested in the single-dose study ranged from 0.005 mL/kg to 0.100 mL/kg body weight. In the multiple-dose study, five doses of 0.005 mL/kg to 0.030 mL/kg (0.025-0.150 mL/kg total dose) were evaluated. Studies were single-masked, placebo-controlled, and safety assessment and adverse events were monitored. RESULTS. All doses in both studies were well tolerated with no treatment-related changes in safety measures for either study. Left ventricular cavity and myocardial enhancement were seen with all doses of MRX-115. CONCLUSIONS. MRX-115 is a promising new intravascular ultrasound contrast agent that was safe and well tolerated at the doses evaluated in these studies.

Original languageEnglish (US)
Pages (from-to)735-740
Number of pages6
JournalInvestigative Radiology
Volume32
Issue number12
DOIs
StatePublished - Dec 1997

Fingerprint

perflutren
Clinical Trials, Phase I
Contrast Media
Microbubbles
Gases
Single-Blind Method
Lipids
Safety
Fluorocarbons
Pharmaceutical Preparations
Placebos
Body Weight

Keywords

  • Contrast agents
  • Echocardiography
  • Microbubbles
  • Ultrasound

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Phase I clinical trials of MRX-115 : A new ultrasound contrast agent. / Fritz, Thomas A.; Unger, Evan C; Sutherland, George; Sahn, David.

In: Investigative Radiology, Vol. 32, No. 12, 12.1997, p. 735-740.

Research output: Contribution to journalArticle

Fritz, Thomas A. ; Unger, Evan C ; Sutherland, George ; Sahn, David. / Phase I clinical trials of MRX-115 : A new ultrasound contrast agent. In: Investigative Radiology. 1997 ; Vol. 32, No. 12. pp. 735-740.
@article{9ef763dd93e64d42836a20a99ab858c6,
title = "Phase I clinical trials of MRX-115: A new ultrasound contrast agent",
abstract = "RATIONALE AND OBJECTIVES. Stabilized microbubbles are under development as contrast agents for medical ultrasound. The authors report the results of Phase I clinical trials of a new ultrasound contrast agent based on lipid- encapsulated perfluorocarbon gas microbubbles. METHODS. Lipids encapsulating perfluoropropane gas (Aerosomes{\circledR} MRX-115, ImaRx Pharmaceutical Corp., Tucson, AZ) were evaluated in Phase I clinical trials. Two separate studies were performed. The first was a single escalating-dose study (n = 30 subjects), and the second was a multiple-dose study (n = 18 subjects) with rechallenge in several subjects (n = 4) after 21 days. Echocardiographic examinations were performed before and after contrast agent for each test drug administration for both studies, with the exception of the rechallenge group. Doses tested in the single-dose study ranged from 0.005 mL/kg to 0.100 mL/kg body weight. In the multiple-dose study, five doses of 0.005 mL/kg to 0.030 mL/kg (0.025-0.150 mL/kg total dose) were evaluated. Studies were single-masked, placebo-controlled, and safety assessment and adverse events were monitored. RESULTS. All doses in both studies were well tolerated with no treatment-related changes in safety measures for either study. Left ventricular cavity and myocardial enhancement were seen with all doses of MRX-115. CONCLUSIONS. MRX-115 is a promising new intravascular ultrasound contrast agent that was safe and well tolerated at the doses evaluated in these studies.",
keywords = "Contrast agents, Echocardiography, Microbubbles, Ultrasound",
author = "Fritz, {Thomas A.} and Unger, {Evan C} and George Sutherland and David Sahn",
year = "1997",
month = "12",
doi = "10.1097/00004424-199712000-00003",
language = "English (US)",
volume = "32",
pages = "735--740",
journal = "Investigative Radiology",
issn = "0020-9996",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Phase I clinical trials of MRX-115

T2 - A new ultrasound contrast agent

AU - Fritz, Thomas A.

AU - Unger, Evan C

AU - Sutherland, George

AU - Sahn, David

PY - 1997/12

Y1 - 1997/12

N2 - RATIONALE AND OBJECTIVES. Stabilized microbubbles are under development as contrast agents for medical ultrasound. The authors report the results of Phase I clinical trials of a new ultrasound contrast agent based on lipid- encapsulated perfluorocarbon gas microbubbles. METHODS. Lipids encapsulating perfluoropropane gas (Aerosomes® MRX-115, ImaRx Pharmaceutical Corp., Tucson, AZ) were evaluated in Phase I clinical trials. Two separate studies were performed. The first was a single escalating-dose study (n = 30 subjects), and the second was a multiple-dose study (n = 18 subjects) with rechallenge in several subjects (n = 4) after 21 days. Echocardiographic examinations were performed before and after contrast agent for each test drug administration for both studies, with the exception of the rechallenge group. Doses tested in the single-dose study ranged from 0.005 mL/kg to 0.100 mL/kg body weight. In the multiple-dose study, five doses of 0.005 mL/kg to 0.030 mL/kg (0.025-0.150 mL/kg total dose) were evaluated. Studies were single-masked, placebo-controlled, and safety assessment and adverse events were monitored. RESULTS. All doses in both studies were well tolerated with no treatment-related changes in safety measures for either study. Left ventricular cavity and myocardial enhancement were seen with all doses of MRX-115. CONCLUSIONS. MRX-115 is a promising new intravascular ultrasound contrast agent that was safe and well tolerated at the doses evaluated in these studies.

AB - RATIONALE AND OBJECTIVES. Stabilized microbubbles are under development as contrast agents for medical ultrasound. The authors report the results of Phase I clinical trials of a new ultrasound contrast agent based on lipid- encapsulated perfluorocarbon gas microbubbles. METHODS. Lipids encapsulating perfluoropropane gas (Aerosomes® MRX-115, ImaRx Pharmaceutical Corp., Tucson, AZ) were evaluated in Phase I clinical trials. Two separate studies were performed. The first was a single escalating-dose study (n = 30 subjects), and the second was a multiple-dose study (n = 18 subjects) with rechallenge in several subjects (n = 4) after 21 days. Echocardiographic examinations were performed before and after contrast agent for each test drug administration for both studies, with the exception of the rechallenge group. Doses tested in the single-dose study ranged from 0.005 mL/kg to 0.100 mL/kg body weight. In the multiple-dose study, five doses of 0.005 mL/kg to 0.030 mL/kg (0.025-0.150 mL/kg total dose) were evaluated. Studies were single-masked, placebo-controlled, and safety assessment and adverse events were monitored. RESULTS. All doses in both studies were well tolerated with no treatment-related changes in safety measures for either study. Left ventricular cavity and myocardial enhancement were seen with all doses of MRX-115. CONCLUSIONS. MRX-115 is a promising new intravascular ultrasound contrast agent that was safe and well tolerated at the doses evaluated in these studies.

KW - Contrast agents

KW - Echocardiography

KW - Microbubbles

KW - Ultrasound

UR - http://www.scopus.com/inward/record.url?scp=0031453226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031453226&partnerID=8YFLogxK

U2 - 10.1097/00004424-199712000-00003

DO - 10.1097/00004424-199712000-00003

M3 - Article

C2 - 9406013

AN - SCOPUS:0031453226

VL - 32

SP - 735

EP - 740

JO - Investigative Radiology

JF - Investigative Radiology

SN - 0020-9996

IS - 12

ER -